Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instituto RosenbuschBUE:ROSE -0.32%37 PS Ratio is 1.05 as of Jul. 16, 2026, which is 123% above its 10-year median of 0.47. GuruFocus rates BUE:ROSE with a GF Score™ of 37/100 and a GF Value™ of ARS62.16 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Instituto Rosenbusch ranks better than 74.24% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Instituto Rosenbusch's share price is ARS157.50.
Instituto Rosenbusch's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was ARS150.36. Hence, Instituto Rosenbusch's PS Ratio for today is 1.05.
The historical rank and industry rank for Instituto Rosenbusch's PS Ratio or its related term are showing as below:
BUE:ROSE'
s PS Ratio Range Over the Past 10 Years
Min: 0.14 Med: 0.47 Max: 2.18
Current: 1.05
During the past 13 years, Instituto Rosenbusch's highest PS Ratio was 2.18. The lowest was 0.14. And the median was 0.47.
BUE:ROSE's PS Ratio is ranked better than 74.24% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.37
vs BUE:ROSE: 1.05
Instituto Rosenbusch SA revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Instituto Rosenbusch was -41.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 62.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 60.70% per year.
During the past 13 years, Instituto Rosenbusch's highest 3-Year average Revenue per Share Growth Rate was 127.00% per year. The lowest was -80.70% per year. And the median was 16.00% per year.
Back to Basics: PS Ratio
Instituto Rosenbusch (BUE:ROSE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Instituto Rosenbusch PS Ratio Related Terms
Instituto Rosenbusch PS Ratio Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's PS Ratio distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Instituto Rosenbusch's Share Price of today is ARS157.50. Instituto Rosenbusch's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS150.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Instituto Rosenbusch (BUE:ROSE) has a PS Ratio of 1.05 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Instituto Rosenbusch and its competitors. This is 123% above median its historical median of 0.47. Over the past decade, Instituto Rosenbusch's PS Ratio has ranged from 0.14 to 2.18. According to the industry distribution chart, Instituto Rosenbusch ranks #246 out of 955 companies in the Drug Manufacturers industry, placing it in the top 25.8%.
Is Instituto Rosenbusch's PS Ratio too high?
Instituto Rosenbusch's current PS Ratio of 1.05 is 123% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 2.18. The Drug Manufacturers industry median PS Ratio is 2.37. Instituto Rosenbusch's value of 1.05 is 55.7% below this industry median. Based on the distribution chart, Instituto Rosenbusch ranks #246 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #246 out of 955 companies for PS Ratio. This puts Instituto Rosenbusch in the upper half of its industry. The industry median PS Ratio is 2.37. Instituto Rosenbusch's value of 1.05 is 55.7% below this benchmark. Historically, Instituto Rosenbusch's own PS Ratio has ranged from 0.14 to 2.18 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 2.37, Instituto Rosenbusch has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.37, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current PS Ratio of 1.05 is 55.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current PS Ratio is 1.05, which is 123% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.16, compared to a current price of ARS157.50 — trading 153.4% above its estimated fair value. The current PS Ratio is 1.05, which is 123% above median its 10-year median of 0.47 and 55.7% below the Drug Manufacturers industry median of 2.37. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current PS Ratio is 1.05 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS157.50 is trading 153.4% above its estimated GF Value™ of ARS62.16.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
PS Ratio: 1.05 (123% above median its 10-year median of 0.47)
GF Value™: ARS62.16 vs. price of ARS157.50 (153.4% above fair value)
Industry Position: 55.7% below the Drug Manufacturers median (#246 of 955)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score
Get the complete analysis for BUE:ROSE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
